Concepedia

Yiyun Tang

YT

40

Publications

4.5K

Citations

25

H-Index

2011

Active since

Affiliations

Pfizer (United States)(Current)

University of South China

Massachusetts General Hospital

First Affiliated Hospital of University of South China

Dana-Farber Cancer Institute

Yiyun Tang is an author at Pfizer (United States) specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2011–2023

40

Publications

40

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations · Full text

, , +10

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon et al. · The Lancet Oncology · 2011 · 880 citations

, , +7

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2018 · 406 citations

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

Stephen J. Freedland, Murilo Luz, Ugo De Giorgi et al. · New England Journal of Medicine · 2023 · 245 citations

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett et al. · Annals of Oncology · 2014 · 220 citations · Full text

Rows per page

1–5 of 40